Intermediate monocytes lead to enhanced myocardial remodelling in STEMI patients with diabetes

International Heart Journal

Volumn 56, Issue 1, 2015, Pages 22-28

  Lu, Wenbin ^a,b   Zhang, Ziwei ^b   Fu, Cong ^a   Ma, Genshan ^a  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

CD14; CD16; Myocardial infarction

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR; CHOLESTEROL; CREATINE KINASE MB; CREATININE; D6 CHEMOKINE DECOY RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOGLOBIN; TROPONIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD14+ MONOCYTE; CD16+ MONOCYTE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FLOW CYTOMETRY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MONOCYTE; MYOCARDIAL DISEASE; MYOCARDIAL REMODELLING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THREE DIMENSIONAL ECHOCARDIOGRAPHY; BLOOD; COMORBIDITY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART VENTRICLE REMODELING; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSIOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; STATISTICS;

AGED; CHEMOKINE CCL2; COMORBIDITY; DIABETES MELLITUS; ELECTROCARDIOGRAPHY; FEMALE; FLOW CYTOMETRY; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; STATISTICS AS TOPIC; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84921879173     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-174     Document Type: Article

References (38)

1. Legein B, Temmerman L, Biessen EA, Lutgens E. Infammation and immune system interactions in atherosclerosis. Cell Mol Life Sci 2013; 70: 3847-69. (Review)
2. Czepluch FS, Schlegel M, Bremmer F, Behnes CL, Hasenfuss G, Schäfer K. Stage-dependent detection of CD14+ and CD16+ cells in the human heart after myocardial infarction. Virchows Arch 2013; 463: 459-69.
3. Sheu JJ, Chang LT, Chiang CH, et al. Prognostic value of activated toll-like receptor-4 in monocytes following acute myocardial in-farction. Int Heart J 2008; 49: 1-11.
4. Charo IF. Blinding the monocytes to protect the heart. Circulation 2013; 127: 2006-8.
5. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct infammation and repair after myocardial infarction. Circulation 2010; 121: 2437-45. (Review)
6. Zawada AM, Rogacev KS, Rotter B, et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118: e50-61.
7. Cros J, Cagnard N, Woollard K, et al. Human CD14dim mono-cytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33: 375-86.
8. Ghattas A, Griffiths HR, Devitt A, Lip G Y, Shantsila E. Mono-cytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol 2013; 62: 1541-51. (Review)
9. Merino A, Buendia P, Martin-Malo A, Aljama P, Ramirez R, Car-raedo J. Senescent CD14+CD16+ monocytes exhibit proinfam-matory and proatherosclerotic activity. J Immunol 2011; 186: 1809-15.
10. Thorstensen A, Dalen H, Hala P, et al. Three-dimensional echocar-diography in the evaluation of global and regional function in patients with recent myocardial infarction: a comparison with magnetic resonance imaging. Echocardiography 2013; 30: 682-92.
11. McKimmie CS, Fraser AR, Hansell C, et al. Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J Immunol 2008; 181: 8171-81.
12. Graham GJ, Locati M. Regulation of the immune and infamma-tory responses by the ‘atypical’ chemokine receptor D6. J Pathol 2013; 229: 168-75. (Review)
13. Vieira ML, Oliveira WA, Cordovil A, et al. 3D Echo pilot study of geometric left ventricular changes after acute myocardial infarction. Arq Bras Cardiol 2013; 101: 43-51. (English, Portuguses)
14. Lemkes J, Nijveldt R, Beek AM, et al. Evaluating the Optimal Timing of Revascularization in Patients with Transient ST-Seg-ment Elevation Myocardial Infarction: Rationale and Design of the TRANSIENT Trial. J Cardiovasc Transl Res 2014; 7: 590-6.
15. Kamei M, Carman CV. New observations on the traffcking and diapedesis of monocytes. Curr Opin Hematol 2010; 17: 43-52. (Review)
16. Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1424-32. (Review)
17. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to infammatory sites. Science 2009; 325: 612-6.
18. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
19. Rogacev KS, Seiler S, Zawada AM, et al. CD14++CD16+ mono-cytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32: 84-92.
20. Heine GH, Ortiz A, Massy ZA, et al. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Neph-rol 2012; 8: 362-9. (Review)
21. Marketou ME, Kontaraki JE, Tsakountakis NA, et al. Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension. Am J Cardiol 2011; 107: 59-63.
22. Abeles RD, McPhail MJ, Sowter D, et al. CD14, CD16 and HLA-DR reliably identifes human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg) monocytes: Expansion of CD14(hi)/CD16(pos) and contraction of CD14(lo) /CD16(pos) monocytes in acute liver failure. Cytometry A 2012; 81: 823-34.
23. Xiu F, Stanojcic M, Diao L, Jeschke MG. Stress hyperglycemia,insulin treatment, and innate immune cells. Int J Endocrinol 2014; 2014: 486403. (Review)
24. Kumar P, Rao GN, Pal BB, Pal A. Hyperglycemia-induced oxida-tive stress induces apoptosis by inhibiting PI3-kinase/Akt and ERK 1/2 MAPK mediated signaling pathway causing downregu-lation of 8-oxoG-DNA glycosylase levels in glial cells. Int J Bio-chem Cell Biol 2014; 53: 302-19.
25. Komiya N, Hirose H, Saisho Y, Saito I, Itoh H. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. Int Heart J 2008; 49: 681-9.
26. Rogacev KS, Cremers B, Zawada AM, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512-20.
27. Montange D, Davani S, Deschaseaux F, et al. The number of circulating CD14 (+) cells is related to infarct size and post infarct volumes in ST segment elevation myocardial infarction but not non-ST segment elevation myocardial infarction. Exp Clin Cardiol 2012; 17: 131-5.
28. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and infammation. J Leukoc Biol 2007; 81: 584-92. (Review)
29. Belge KU, Dayyani F, Horelt A, et al. The pro-inflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-42.
30. Hristov M, Leyendecker T, Schuhmann C, et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-4.
31. Liu Y, Imanishi T, Ikejima H, et al. Association between circulating monocyte subsets and in-stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction. Circ J 2010; 74: 2585-91.
32. Cancellieri C, Caronni N, Vacchini A, et al. Review: Structure-function and biological properties of the atypical chemokine receptor D6. Mol Immunol 2013, 55: 87-93. (Review)
33. Heine GH, Ulrich C, Seibert E, et al. CD14(++) CD16+ mono-cytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008; 73: 622-9.
34. Berg KE, Ljungcrantz I, Andersson L, et al. Elevated CD14++ CD16- monocytes predict cardiovascular events. Circ Cardiovasc Genet 2012; 5: 122-31.
35. Hilgendorf I, Swirski FK. Making a difference: monocyte heterogeneity in cardiovascular disease. Curr Atheroscler Rep 2012; 14: 450-9. (Review)
36. Spahn JH, Kreisel D. Monocytes in sterile infammation: recruitment and functional consequences. Arch Immunol Ther Exp (Warsz) 2014; 62: 187-94.
37. Braesch-Andersen S, Paulie S, Smedman C, Mia S, Kumagai-Braesch M. ApoE production in human monocytes and its regulation by infammatory cytokines. PLoS One 2013; 8: e79908.
38. Luis SA, Yamada A, Khandheria BK, et al. Use of three-dimensional speckle-tracking echocardiography for quantitative assessment of global left ventricular function: a comparative study to three-dimensional echocardiography. J Am Soc Echocardiogr 2014; 27: 285-91.